Kooij Louise Frederika

Chief Accounting OfficerNewAmsterdam Pharma Co N.V. (NAMS) · full profile →Form 4 · filed Jul 22, 2026
Net Selling
Open-Market Buys
$0
Open-Market Sells
$3.2M
Net Open-Market Flow
-$3.2M
Transactions
7
5 non-derivative · 2 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Jul 20, 2026Option exercise(M)25K$11.90$298K49K
Jul 20, 2026Option exercise(M)80K$11.17$894K129K
Jul 20, 2026Sell(S)70K$29.96$2.1M59K
Jul 20, 2026Sell(S)32K$31.05$990K27K
Jul 20, 2026Sell(S)3K$31.71$92K24K

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Jul 20, 2026Option exercise(M)25K$010K
Jul 20, 2026Option exercise(M)80K$070K

Transaction Codes

M
Option exercise / conversion
S
Open-market sale

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001193125-26-312387) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

Build

Build on these Form 4 transactions

The public view is the crawlable proof. The same sourced dataset is available through REST and MCP for agents, research scripts, and back-office tools.